Imagine a success in the treatment of cancer where only deadly cells are targeted, sparing healthy host cells; Or patients with abnormal protein synthesis are treated to produce a healthy protein. Hiroshi Abe and his colleagues at Nagoya University have identified two applications, in a new study.
